Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

2004-08-01

Additional Metadata
Keywords	9-nitrocamptothecin, Oral chemotherapy, Topoisomerase I inhibitors, Urothelial tract tumors
Persistent URL	doi.org/10.1023/B:DRUG.0000026260.24275.02, hdl.handle.net/1765/69844
Journal	Investigational New Drugs: the journal of new anti-cancer agents
Organisation	Department of Medical Oncology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Jonge, M., Droz, J.-P., Paz-Ares, L., van Oosterom, A., de Wit, R., Chollet, P., Baron, B., Lacombe, D., Mettinger, K.& Fumoleau, P. (2004). Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Investigational New Drugs: The Journal of New Anti-cancer Agents, 22(3), 329–333.https://doi.org/10.1023/B:DRUG.0000026260.24275.02

Publication